Trial reportInternational journal of colorectal disease2005
Oral budesonide therapy improves quality of life in patients with collagenous colitis.
Trial report in International journal of colorectal disease, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Heterogeneity in Histological Evaluation of Microscopic Colitis in Randomized Clinical Trials: An Umbrella Review.Inflammatory bowel diseases · 2026Pooled it
- Interventions for treating collagenous colitis.The Cochrane database of systematic reviews · 2017Pooled it
- Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial.International journal of colorectal disease · 2007Trial
- European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations.United European gastroenterology journal · 2021Article
- Microscopic colitis impacts quality of life in older people.BMJ case reports · 2019Article
- Prevalence, Pathogenesis, Diagnosis, and Management of Microscopic Colitis.Gut and liver · 2018Review
- High prevalence of irritable bowel syndrome-type symptoms in microscopic colitis: implications for treatment.Therapeutic advances in gastroenterology · 2018Article
- Microscopic Colitis: A Review of Collagenous and Lymphocytic Colitis.Gastroenterology & hepatology · 2017Article
- Diagnosis and Management of Microscopic Colitis.The American journal of gastroenterology · 2017Review
- Optimal management of collagenous colitis: a review.Clinical and experimental gastroenterology · 2016Review
- Clinical characteristics and patterns and predictors of response to therapy in collagenous and lymphocytic colitis.Scandinavian journal of gastroenterology · 2015Article
- Microscopic colitis: Common cause of unexplained nonbloody diarrhea.World journal of gastrointestinal pathophysiology · 2014Review
- Diagnosis and management of microscopic colitis: current perspectives.Clinical and experimental gastroenterology · 2014Review
- Microscopic colitis: epidemiology, pathophysiology, diagnosis and current management-an update 2013.ISRN gastroenterology · 2013Article
- Microscopic colitis.World journal of gastroenterology · 2012Review
- Review of the microscopic colitides.Current gastroenterology reports · 2011Review
- Recent advances in diagnosis and treatment of microscopic colitis.Annals of gastroenterology · 2011Review
- Therapeutic benefits of budesonide in gastroenterology.Therapeutic advances in chronic disease · 2010Article
- Diagnosis and management of microscopic colitis.World journal of gastroenterology · 2008Review
- Microscopic colitis: an approach to treatment.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCollagenous colitis is an idiopathic microscopic colitis characterised by watery diarrhoea. The impact of collagenous colitis on quality of life has not been assessed. Our aim was to assess quality of life in patients with this condition and compare the effect of treatment with budesonide capsules or placebo on this parameter.
methodsPatients with chronic diarrhoea and histologically-proven collagenous colitis were randomised to receive either budesonide controlled-release capsules (Entocort capsules, AstraZeneca, Lund, Sweden), 9 mg/day, or placebo for 6 weeks. Quality of life was measured using the validated Gastrointestinal Quality of Life Index (GIQLI) at baseline and after 6 weeks. With the GIQLI, scores range from 0 to 144, with higher scores representing better quality of life.
resultsComplete quality of life assessment was available in 29 patients (budesonide: n=17; placebo: n=12). At baseline, quality of life was low in patients with collagenous colitis (mean 76). After 6 weeks of treatment, the mean GIQLI score increased significantly in the budesonide group (from 67 to 92, p<0.001), but remained unchanged in the placebo group (86-88). The mean score of the dimensions symptoms (p=0.001), emotional functioning (p=0.003) and physical functioning (p=0.017) increased significantly in the budesonide group compared with the placebo group. A significantly larger proportion of patients in the budesonide group experienced improved stool consistency (p<0.01) and a significant reduction in the mean stool frequency compared with those in the placebo group (p<0.01).
conclusionQuality of life is seriously reduced in patients with collagenous colitis. Six-week treatment with oral budesonide controlled-release capsules significantly improves quality of life and clinical symptoms compared with placebo in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.